Front Runners: Celldex Therapeutics (CLDX), Activision Blizzard (ATVI), Net Element (NETE), Lexicon Pharmaceuticals (LXRX)

Celldex Therapeutics (CLDX) has been a solid gainer in mid-day trading, up more than 12% to $21.00 from Wednesday’s close of $18.73. The move comes on a big volume too with the issue currently trading more than 7 million shares, which dwarfs the average volume of 2.56M. Not seeing any news to account for the move. The name however, continues to show strength as price extends its breakout over $19.50 level.

Celldex Therapeutics is a Hampton, New Jersey-based biopharmaceutical company. Its stock has a median consensus analyst price target of $33 with a high target of $45, and a 52-week trading range of $10.76 to $33.33.

The T-12 price/sales at Celldex is 614.88. CLDX‘s revenue for the same period is $2.73 million.

Celldex Therapeutics has market cap of $1.88 billion.

Shares of Activision Blizzard, Inc. (ATVI) are higher by 7.23% to $20.99 on heavy volume in midday trading on Thursday. The move follows reports stating that a record $275M agreement has been reached to settle a consolidated derivative and class action shareholder case opposing the company’s 2013 deal to acquire its stock that was held by Vivendi SA.

On valuation measures, Activision Blizzard, Inc. shares are currently priced at 24.68x this year’s forecasted earnings compared to the industry’s 25.26x earnings multiple. Ticker has a PEG and forward P/E ratio of 0.85 and 14.67, respectively. Price/sales for the same period is 3.23 while EPS is $0.85. Currently there are 21 analysts that rate ATVI a ‘Buy’ and  1 rating it a ‘Hold’. No analysts rates it a ‘Sell’. ATVI has a median Wall Street price target of $26.00 with a high target of $31.00.

In the past 12 months, shares of Santa Monica, Calif.-based videogame maker have traded between a low of $16.55 and a high of $24.18. Shares are up 16.98% year-over-year, and 10.82% year-to-date.

Net Element, Inc. (NETE) is trading at unusually high volume Thursday with 5.7 million shares changing hands. It is currently at 2x its average daily volume and trading up 33% at $1.75. Not seeing any news or rumors to account for the move.

Net Element, Inc. is a North Miami Beach, Florida.-based technology company that specializes in mobile commerce and payment processing. Its stock has a 52-week trading range of $0.88 to $5.75. The T-12 operating margin at Net Element is (117.68%). The name‘s revenue for the same period is $21.54 million.

Shares in the $77.10 million company are down 69.95% year-to-date, compared with an 14.08% gain in the S&P 500.

Shares of Lexicon Pharmaceuticals, Inc (LXRX) plunged 18% in mid-day market trading Thursday after announcing a $50 million common stock offering. Lexicon said it intends to grant the underwriters a 30-day option to purchase up to $7,500,000 of additional shares of common stock.

Lexicon Pharmaceuticals has a price-to-earnings growth ratio of (0.19). Price/Sales is 231.32, while EPS is ($0.22). Currently there are 6 analysts that rate LXRX a ‘Buy’, and 2 rating it a ‘Hold’. No analyst rates it a ‘Sell’. LXRX has a median Wall Street price target of $3.00 with a high target of $3.50.

LXRX shares recently lost $0.23 to $1.02. In the past 12 months, shares of The Woodlands, Texas-based company have traded between a low of $0.96 and a high of $2.45. Shares are down 42.92% year-over-year, and 30.56% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*